EU approves new dosing schedule for MSD’s Keytruda
The less frequent dosing gives both patients and oncologists more flexibility, helping to free up hospitals.
Read More
Tag: dosing
BMS’ Opdivo cleared for monthly use
US regulators have approved a label update to Bristol-Myers Squibb’s Opdivo, waving through a new dosing option for the immunotherapy of every four weeks.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
